Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Rabin Medical Center1 enrolled

Overview

The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Parkinson Disease

Interventions

OpicaponeDRUG

25mg or 50mg once per day

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * clinical diagnosis with PD * subjects who are willing to participate in the trial. * subjects who participated in the BIA 9-1067-302 clinical trial. Exclusion Criteria: * subjects who didn't take part at the BIA 9-1067-302 clinical trial.

Locations (1)

Rabin Medical Center

Petach Tiqva, Central District, Israel

Outcomes

Primary Outcomes

off periods

number of "off" periods during the day without worsening dyskinesia.

Time frame: 6 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.